Phase I/II trial of weekly nab-paclitaxel as second- or third-line treatment in patients with advanced non-small-cell lung cancer (OLCSG1303)
Phase of Trial: Phase I/II
Latest Information Update: 12 Sep 2017
At a glance
- Drugs Paclitaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 12 Sep 2017 Primary endpoint (Objective clinical response rate) has not been met, according to results presented at the 42nd European Society for Medical Oncology Congress.
- 12 Sep 2017 Results assessing efficacy and tolerability of paclitaxel in patients with advanced non-small-cell lung cancer, were presented at the 42nd European Society for Medical Oncology Congress.
- 28 Dec 2014 Status changed from planning to recruiting as reported by University Hospital Medical Information Network - Japan.